Dementia Associated with Alzimer’s Disease Market [Drug Class: Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, and Combined Drug (Memantine & Donepezil) and Others; Distribution Channel: Hospital Pharmacies, Retail, and Online Sales] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2030

Description

Dementia Treatment Market - Snapshot

The dementia associated with Alzheimer’s disease market is expected to reach a market value of about US$ 6,936.8 Mn by the end of 2026, expanding at a single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of Alzheimer’s across the globe, increased geriatric population, rise in awareness regarding neurodegenerative diseases in developing countries, and rich pipeline of innovative treatment options are expected to boost the dementia associated with Alzheimer’s disease market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the dementia associated with Alzheimer’s disease market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain treatments are expected to hamper the dementia associated with Alzheimer’s disease market.

The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market, in terms of value, as it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of mild to severe dementia. Currently, there is no disease modifying treatment available for Alzheimer’s, and the only approved treatment for the symptomatic relief of AD are cholinesterase inhibitors (Aricept, and memantine. The memantine segment is expected to expand at a notable CAGR, owing to its ability to treat moderate to severe AD and its suitability in cholinergic/ cholinesterase (chE) inhibitors intolerant patients suffering from AD.

In terms of distribution channel, the dementia associated with Alzheimer’s disease market has been segregated into hospital pharmacies, retail, and online sales. The hospital pharmacies segment held a major share of the market in 2017, followed by retail. The hospital pharmacies segment is expected to maintain its market share during forecast period due to availability of cost-effective medications for the treatment of AD. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for the treatment of Alzheimer’s disease.

In terms of geography, the dementia associated with Alzheimer’s disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the dementia associated with Alzheimer’s disease market owing to high awareness regarding Alzheimer’s disease in the U.S. and increased prevalence of AD in the region. According to the World Alzheimer’s Report, Alzheimer’s is the sixth-leading cause of death in the U.S. and currently, more than 5 million Americans are living with Alzheimer’s. Rising incidence of Alzheimer’s in elderly age group and demand for advanced therapies and disease modifying drugs is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure and rising awareness regarding Alzheimer’s in countries such as China and India.

Major players operating in the dementia associated with Alzheimer’s disease market include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

Dementia Associated with Alzheimer’s Disease Market - Snapshot

Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. Dementia associated with Alzheimer's disease is not a normal part of aging. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older. But dementia associated with Alzheimer's disease is not just a disease of old age. Alzheimer's worsens over time. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer's is the sixth leading cause of death in the United States. On average, a person with Alzheimer's lives four to eight years after diagnosis, but can live as long as 20 years, depending on other factors.

Dementia associated with Alzheimer's disease has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with dementia associated with Alzheimer's disease and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing. The most common early symptom of Alzheimer's is difficulty remembering newly learned information.

The most common early symptom of Alzheimer's is difficulty remembering newly learned information because Alzheimer's changes typically begin in the part of the brain that affects learning. As Alzheimer's advances through the brain it leads to increasingly severe symptoms, including disorientation, mood and behavior changes. Signs of dementia associated with Alzheimer’s disease may be more obvious to family members or friends. Anyone experiencing dementia-like symptoms should see a doctor as soon as possible.

The global dementia associated with Alzheimer’s disease market has been segmented as below:

Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
  • Memantine
  • Combined Drug (Memantine & Donepezil) and Others

Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Sales

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dementia Associated with Alzheimer's Disease Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Class Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2016–2026
            4.4.1. Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Projections
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
     5.2. Pipeline Analysis

6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Dementia Associated with Alzheimer's disease Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     6.3.1.1. Donepezil 
                     6.3.1.2. Galantamine
                     6.3.1.3. Rivastigmine
            6.3.2. Memantine 
            6.3.3. Combined Drug (Memantine & Donepezil) and Others
     6.4. Global Dementia Associated with Alzheimer's disease Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            7.3.1. Hospital Pharmacies
            7.3.2. Retail 
            7.3.3. Online Sales 
     7.4. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel 

8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region
     8.1. Key Findings
     8.2. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Region

9. North America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
     9.2. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
            9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     9.2.1.1. Donepezil 
                     9.2.1.2. Galantamine
                     9.2.1.3. Rivastigmine
            9.2.2. Memantine 
            9.2.3. Combined Drug (Memantine & Donepezil) and Others
     9.3. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            9.3.1. Hospital Pharmacies
            9.3.2. Retail 
            9.3.3. Online Sales 
     9.4. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada 
     9.5. North America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
            9.5.1. By Drug Class
            9.5.2. By Distribution Channel 
            9.5.3. By Country

10. Europe Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
            10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     10.2.1.1. Donepezil 
                     10.2.1.2. Galantamine
                     10.2.1.3. Rivastigmine
            10.2.2. Memantine 
            10.2.3. Combined Drug (Memantine & Donepezil) and Others
     10.3. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            10.3.1. Hospital Pharmacies
            10.3.2. Retail 
            10.3.3. Online Sales 
     10.4. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. France
            10.4.3. U.K.
            10.4.4. Italy
            10.4.5. Spain
            10.4.6. Rest of Europe
     10.5. Europe Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
            10.5.1. By Drug Class
            10.5.2. By Distribution Channel 
            10.5.3. By Country/Sub-region

11. Asia Pacific Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     11.2.1.1. Donepezil 
                     11.2.1.2. Galantamine
                     11.2.1.3. Rivastigmine
            11.2.2. Memantine 
            11.2.3. Combined Drug (Memantine & Donepezil) and Others
     11.3. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            11.3.1. Hospital Pharmacies
            11.3.2. Retail 
            11.3.3. Online Sales 
     11.4. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. Japan
            11.4.2. China
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5. Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
            11.5.1. By Drug Class
            11.5.2. By Distribution Channel 
            11.5.3. By Country/Sub-region

12. Latin America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     12.2.1.1. Donepezil 
                     12.2.1.2. Galantamine
                     12.2.1.3. Rivastigmine
            12.2.2. Memantine 
            12.2.3. Combined Drug (Memantine &Donepezil) and Others
     12.3. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            12.3.1. Hospital Pharmacies
            12.3.2. Retail 
            12.3.3. Online Sales 
     12.4. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5. Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
            12.5.1. By Drug Class
            12.5.2. By Distribution Channel 
            12.5.3. By Country/Sub-region

13. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                     13.2.1.1. Donepezil 
                     13.2.1.2. Galantamine
                     13.2.1.3. Rivastigmine
            13.2.2. Memantine 
            13.2.3. Combined Drug (Memantine & Donepezil) and Others
     13.3. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
            13.3.1. Hospital Pharmacies
            13.3.2. Retail 
            13.3.3. Online Sales 
     13.4. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. Israel
            13.4.3. South Africa
            13.4.4. Rest of MEA
     13.5. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
            13.5.1. By Drug Class
            13.5.2. By Distribution Channel 
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis by Company (2016)
     14.3. Market Footprint Analysis
            14.3.1. By Region
            14.3.2. By Drug Class Type
     14.4. Competitive Business Strategies
     14.5. Company Profiles
            14.5.1. Merz Pharma GmbH & Co. KGaA 
                     14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.1.2. Product Portfolio
                     14.5.1.3. SWOT Analysis
                     14.5.1.4. Financial Overview
                     14.5.1.5. Strategic Overview
            14.5.2. Novartis AG  
                     14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.2.2. Product Portfolio
                     14.5.2.3. SWOT Analysis
                     14.5.2.4. Financial Overview
                     14.5.2.5. Strategic Overview
            14.5.3. Allergan plc.
                     14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.3.2. Product Portfolio
                     14.5.3.3. SWOT Analysis
                     14.5.3.4. Financial Overview
                     14.5.3.5. Strategic Overview
            14.5.4. Pfizer, Inc.  
                     14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.4.2. Product Portfolio
                     14.5.4.3. SWOT Analysis
                     14.5.4.4. Financial Overview
                     14.5.4.5. Strategic Overview
            14.5.5. Daiichi Sankyo Company, Limited  
                     14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.5.2. Product Portfolio
                     14.5.5.3. SWOT Analysis
                     14.5.5.4. Financial Overview
                     14.5.5.5. Strategic Overview
            14.5.6. Ono Pharmaceutical Co., Ltd. 
                     14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.6.2. Product Portfolio
                     14.5.6.3. SWOT Analysis
                     14.5.6.4. Financial Overview
                     14.5.6.5. Strategic Overview
            14.5.7. Johnson & Johnson Services, Inc. 
                     14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.7.2. Product Portfolio
                     14.5.7.3. SWOT Analysis
                     14.5.7.4. Financial Overview
                     14.5.7.5. Strategic Overview
            14.5.8. Eisai Co., Ltd. 
                     14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.8.2. Product Portfolio
                     14.5.8.3. SWOT Analysis
                     14.5.8.4. Financial Overview
                     14.5.8.5. Strategic Overview
            14.5.9. H. Lundbeck A/S 
                     14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.9.2. Product Portfolio
                     14.5.9.3. SWOT Analysis
                     14.5.9.4. Financial Overview
                     14.5.9.5. Strategic Overview
            14.5.10. F. Hoffmann-La Roche Ltd.  
                     14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.5.10.2. Product Portfolio
                     14.5.10.3. SWOT Analysis
                     14.5.10.4. Financial Overview
                     14.5.10.5. Strategic Overvie

Choose License Type

Checkout Inquiry Sample